Tag Archives: NAVB
Analysts Offer Insights on Healthcare Companies: Navidea (NYSE MKT: NAVB), GlycoMimetics (NASDAQ: GLYC) and Akero Therapeutics (NASDAQ: AKRO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Navidea (NAVB – Research Report), GlycoMimetics (GLYC – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Navidea (NAVB)
Maxim Group Initiates a Buy Rating on Navidea (NAVB)
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Navidea (NAVB – Research Report) yesterday and set a price target of $2. The company’s shares closed yesterday at $0.68. McCarthy commented: “We are initiating coverage of Buy
